MAIMONIDES MEDICAL CENTER

Similar documents
PHARMACY, MEDICINES & POISONS BOARD

I. Purpose. II. Definitions. Last Approval Date

STANDARD OPERATING PROCEDURES DIVISION OF COMPARATIVE MEDICINE UNIVERSITY OF SOUTH FLORIDA

ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual

In-State Licensee Newsletter January 2007

DRUG ORDERING AND MAINTENANCE

GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY

Contents 1. OVERVIEW APPLICABILITY TRIAL INFORMATION PHARMACY REGISTRATION & SET-UP PHARMACY ACTIVATION PATI

Pharmacy Materials Management Lean and Accountable

FOR IMMEDIATE RELEASE

IND Drug Log Guidelines

NASSAU HEALTH CARE CORPORATION EAST MEADOW, NEW YORK 11554

FACT Common Standards for Cellular Therapies, Second Edition. Summary of Changes

TITLE: MATERIALS MANAGEMENT TABLE OF CONTENTS POLICY #: 13.2 PAGE(S): 12. LOCATION: Administration REVISION DATE(S): 08/30/11; 11/10/08; 05/20/08

Drug Supply Chain Security Act Implementation

ADMINISTRATIVE POLICY MANUAL

Policy and Procedure Manual

DRUG ORDERING AND MAINTENANCE

INVESTIGATIONAL DRUG MANAGEMENT OVERVIEW

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

The following scenario illustrates the supply, receipting and movement of ANODE packs. Allocation and shipment of IMP

3. Efficiently remove the affected product from the marketplace.

GUIDANCE FOR INDUSTRY. Questions and Answers

11.0 FDA-Regulated Research

Inspections, Compliance, Enforcement, and Criminal Investigations

BSWH Technician Continuing Education 2016 Part 2: Pharmacy Law - Controlled Substance Security & Drug Supply Chain Security Act (DSCSA) Contact

TITLE: Implantable Tissue: Receipt, Storage, Use and Documentation

SPECIFICATIONS FOR TENDER #

Chapter 4 Procurement and Transfer of Radioactive Materials

Investigational New Devices

PROPERTY AND INVENTORY MANAGEMENT PROCEDURES

FREQUENTLY ASKED QUESTIONS

Transitioning to Express Scripts

Timeline for the Drug Supply Chain and Security Act

Private Providers FREQUENTLY ASKED QUESTIONS VFC VACCINE ORDERING AND INVENTORY MAINTENANCE IN FLORIDA SHOTS

Nucleus Detailed Reference Guide

Vaccine Management Plan

Maintaining the blind for clinical trials in Pharmacy

Storage of Clinical Trials Materials and Investigational Medicinal Products

IMP Management and Accountability

Supplier questionnaire. 1. Organisation Details (Mandatory) Quality Department Details (or representative)

STUDY REQUEST FORM AND TRAQ DSS FORM

Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products

Procedures for the Use of Controlled Substances in Laboratory and Animal Research

Using RFID for IV Pump Management

ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies

Purchasing and Inventory Control

POLICY Investigational Drug Service Transport

Schedule 3 Services Schedule Equipment and Equipment-Related Supplies

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Presentation of Capabilities Reverse Logistics

Regional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 2

Drug Products, Labeling, and Packaging

Guidance for Industry

In-State Licensee Newsletter MAY 2015

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing

GUIDELINES. Corporate Compliance. Kenneth D. Gibbs President & Chief Executive. Martin A. Cammer Senior Vice President & Corporate Compliance Officer

ESSENTIAL SUPERVISORY JOB FUNCTIONS

Health Job Family: Pharmacy Tech Progression

Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4

The Right Prescription for Working with Investigational Drug Service at BMC

Advancing medication management into the future

Procedures at DF/HCC Transferring Site

URGENT: VOLUNTARY PRODUCT RECALL / MARKET WITHDRAWAL ***LIMITED ONLY TO SPECIFIC LOTS OF DAYTRANA***

Pharmacy Compounding: Infection Prevention

ASBM Biosimilars. Canada Prescribers and Biosimilars October, Kevin Olson, CEO Industry Standard Research

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

Document Title: Handling of drug alerts and recalls of IMPs

SLMTA Management Framework Page 1

Subj: IMPLEMENTATION AND MANAGEMENT OF PRESCRIPTION DRUG TAKE BACK PROGRAM

TJEMS Drug Box Program Best Practices Reviewed: Updated: November 2015

GUIDELINES FOR ISSUING AND RETURNING BLOOD COMPONENTS AND BLOOD PRODUCTS WITHIN A FACILITY

Kansas Pharmacy Act Amendments; Filling and Refilling Prescriptions; Biological Products; Senate Sub. for HB 2055

Temperature Monitoring (Clinical Trials)

Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

Receive Pharmaceutical Stock

ABC Company Recommended Course of Action

CORPORATE POLICIES AND PROCEDURES. GIFTS NO.: (Formerly ADM X 260)

PARTS ORDERING AND RETURN POLICY PROCEDURES

POINT Clinical Research Collaboration SOP-DH-CA.01 v2.0 POINT Trial Canadian Clinical Sites: Study Drug Handling Effective Date: 08/30/2013

TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17

Pharmacogenomics within the EHR

10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

A Wholesaler s Point of View on UDI

ANDREW BALO SENIOR VICE PRESIDENT, REGULATORY, BIOMETRICS, & CLINICAL AFFAIRS DEXCOM, INC 6340 SEQUENCE DRIVE SAN DIEGO, CA 92121

Tuesday, 28 April Recalls & Advertising Section Therapeutic Goods Administration PO Box 100 WODEN ACT 2606

Optimizing Inpatient Pharmacy Operations. Quality Safety Efficiency Profitability

VENDOR ACCESS AND CONDUCT POLICY

Clinical Trial Unit, Hospital Pharmacy Central Denmark Region

Medical-surgical supplies are essential to the delivery of health care.

Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility

Transitioning to Express Scripts Frequently Asked Questions

General Quality Assurance Procedure (QAP) QAP: 13.0 Subject: Control of Nonconforming Product Date: 11/21/13 Created By: Approved By: Rev: C

QUALITY AGREEMENT. The following Agreement has been concluded between

Perfect Order and Beyond

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

Transcription:

MAIMONIDES MEDICAL CENTER CODE: AD-088 (Revised) ORIGINALLY ISSUED: October 2, 1990 SUBJECT: Product Safety Recall and Alert I POLICY In the event of a product safety recall or alert of a medical device or item, or any equipment, supply or material used by the Medical Center, it is the policy of Maimonides Medical Center to implement prescribed vendor or regulatory agency actions without delay. Product safety recalls and alerts involving pharmaceuticals are addressed in PHARM-045 Safety recalls involving food are addressed in Food & Nutrition policy no. 3.B.13(1) Expired Products and Product Recall (attachment A). II RESPONSIBILITIES 1. It is the responsibility of any individual who is made aware of a product safety recall or alert of a medical device or item, or any equipment, supply or material to immediately notify their supervisor or department head (or designee) of such notice. 2. It is the responsibility of the supervisor or department head (or designee) to insure timely notification to the Safety Department of the product safety recall or alert notice. 3. It is the responsibility of the Safety Department to forward all safety recall alerts to all departments that may be affected by the notice. If applicable, the department(s) affected will implement the recommended actions on a timely basis and to maintain documentation of the actions related to any product safety recall or alert for biomedical equipment. 4. It is the responsibility of the Senior Vice President for Support Services (or designee) to implement the recommended actions on a timely basis and to maintain documentation related to any product safety recall or alert for equipment or supplies related to the physical plant. 5. It is the responsibility of the Vice President for Professional Affairs to inform the Vice President for Legal Affairs about any product safety alert or recall which may have potential medical-legal implications for the Medical Center.

6. It is the responsibility of the Director of Material Management and Purchasing [or designee] to inform all vendors of their obligation to notify the Purchasing Department in writing by registered letter of any product safety recall or alert, insure timely notification to the user departments, Warehouse and Medical Supply Department, and maintain records related to the notices and documentation of compliance. III PROCEDURES 1. Any individual becoming aware of a product safety recall or alert must immediately notify their supervisor or department head [or designee] regarding such notice. 2. The supervisor or department head [or designee] should notify the Safety Department of the product safety recall or alert and forward all related documentation. 3. The Safety Department will log all notices and maintain a file of the notices and departmental responses, and follow-up with the departments to assure response is received. A. Product Safety Recall and Alert General Products 1. The Safety Department will identify the known and potential user department(s) of the product, and the areas in which stock may be stored and from which distributed, and communicate the recommended actions. 2. The supervisor or department head (or designee) should identify if there are in possession of the identified product, take the actions recommended in the product safety recall or alert, and forward documentation of the actions to the Safety Department. 3. If the product safety recall or alert has potential medical-legal implications, the Sr. Vice President for Professional Affairs will advise the Executive Vice President for Legal Affairs. B. Product Safety Recall or Alert Involving Bio-Medical Equipment 1. If the product safety recall or alert involves biomedical equipment, the Director of Bio-Medical Engineering is to be immediately notified, concurrent with the notification to the Safety Department. 2. The Director of Bio-Medical Engineering will identify the known and potential user departments of the product, and the areas where the product may be stored or from which distributed. 2

3. The Director of Bio-Medical Engineering will arrange for compliance with the recommendations of the product safety alert or recall, and coordinate the timely removal, repair or return of the equipment, as appropriate, including coordinating the activities with the product manufacturer. 4. Documentation regarding full compliance with the details of the product safety alert or recall will be maintained by the Director of Bio-Medical Engineering, with copies to the Safety Department. C. Product Safety Recall and Alert of Equipment, Supplies and Material Related to the Physical Plant 1. If the product safety recall or alert involves equipment, supplies and material related to the physical plant, the Senior Vice President for Support Services (or designee) will be notified by the Safety Department. 2. The Senior Vice President for Support Services (or designee) will identify the known and potential user departments of the product, and the areas where the product may be stored or from which distributed and other areas affected by the product. 3. The Senior Vice President for Support Services (or designee) will arrange for compliance with the recommendations of the product safety recall or alert notices involving equipment, supplies or materials related to the physical plant, and coordinate the removal, repair or return of the equipment, as appropriate, including coordinating the activities with the product manufacturer. 4. Documentation regarding full compliance with the details of the product safety alert or recall will be maintained by the Senior Vice President for Support Services, with copies sent to the Safety Departments. IV CONTROLS 1. The Director of Materials Management and Purchasing will implement procedures for all vendors from whom products are procured to notify the Medical Center in writing of all product safety recalls and alerts. 2. The Director of Bio-Medical Engineering will include information related to product safety recall and alert in the department s performance improvement reports. 3

3. The Safety Department will include information related to product safety recall and alert notices in its report to the Environment of Care Committee. Kenneth D. Gibbs President & CEO KK REFERENCE: Pharm-045 Drug Recall INDEX: Alert/Recall of Medical Device(s)/Item(s) ORIGINATING DEPARTMENT: Safety LIST OF ATTACHMENTS: Attachment A - Food & Nutrition policy no. 3.B.13 (1)- Expired Products and Product Recall 4

ATTACHMENT A CODE: PHARM 45 (Revised) DATE: January 26, 2017 ORIGINALLY ISSUED: October 28, 2004 MAIMONIDES MEDICAL CENTER SUBJECT: DRUG RECALL I. POLICY: Upon notification that a drug or pharmaceutical product has been recalled or discontinued by the manufacturer, vendor, or the U.S. Food and Drug Administration (FDA) for safety reasons, the Pharmacy will review the severity of recall notice, actions to be taken, coordinate the removal, sequestering and disposal of such items from all Pharmacy dispensing areas, including RobotRx, MedCarousel and Pyxis stations, medication storage sites, kits that contain medications, all hospital off-site and offcampus areas in which drugs are handled or used. Upon notification of a product recall or discontinuation for safety reasons, Pharmacy will generate an alert to hospital clinicians, such as prescribers and those who administer medication and will present it to the Medication Use and Pharmacy and Therapeutics Committees. The message would clearly state medication name, manufacturer s name, lot number(s) and reason for the recall. When Pharmacy is informed of a product recall of substantial clinical significance, patients will be identified, informed of the recall and advised of any necessary action as required. II. RESPONSIBILITY: A. It is the responsibility of the Director of Pharmacy or designee to oversee the management of the drug recall procedure. B. Pharmacy will coordinate the identification and notification of patients who may have received a recalled or discontinued medication for safety concerns of substantial clinical significance during their admission or during an off-site ambulatory care area visit. C. It is the responsibility of the Inventory Control Manager and the Evening Manager to coordinate the removal of recalled items from all areas. D. Risk Management will assist with the notification of patients regarding drug recalls for safety concerns of clinical significance. 5

III. PROCEDURES: A. Various sources of recall notices (FDA alerts, Distributors, Manufacturers, etc) are received by the Pharmacy Purchasing Manager. B. The Pharmacy Purchasing Manager will review the severity of the recall notice and action(s) to be taken and will discuss with the Director of Pharmacy and/or Pharmacy Safety Officer as appropriate. C. The Pharmacy Purchasing Manager will review all electronic invoices and purchase history to determine if the recalled drug has been purchased by the Pharmacy. D. The Pharmacy Purchasing Manager will attempt to find out from vendors, distributors if affected recalled products were purchased, distributed/sent to the Pharmacy Department. E. The Pharmacy Purchasing Manager in conjunction with other team members will coordinate the inspection and removal of recalled items from all Pharmacy medication storage areas (as listed in Drug Recall Report Form), including RobotRx, MedCarousel and Pyxis stations, kits that contain medications, Pharmacy satellite locations, Emergency Department, intensive care areas, Anesthesiology, Nuclear Medicine, Radiology, Blood Bank, off-site ambulatory locations, emergency boxes and all other patient care areas in which drugs are handled and used. F. Each affected recalled item will be recorded in the Product Recall spreadsheet that will include the following information, Date of Notice Material Description Material Strength Dosage form Reason for the recall Manufacture item number Manufacturer Manufacturer NDC Affected LOT# Affected expiration date Manufacturer initial shipped date Action taken (specific hospital locations inspected for removal of the recalled items) G. To ensure the timely retrieval of all recalled drugs from unit dose dispensing areas including RobotRx, MedCarousel and Pyxis stations and from patients who may be current recipients of the recalled item, the Pharmacy will generate a computerized Target Drug Report for the drug in question. The Target Drug Report will list the name and location of all patients receiving the recalled drug. In the case of product recalls of substantial clinical significance, Pharmacy, in collaboration with Risk Management, will inform the attending physician and the patient of the recall. H. Pharmacy will notify personnel at off-site ambulatory patient care areas of any recalled or discontinued products dispensed by the Hospital Pharmacy. When necessary, owing to a safety concern of clinical significance, each site will identify and collaborate with Risk Management to notify patients and their physicians of the drug recall. 6

I. A record of the Drug Recall Report Form will be maintained electronically in Pharmacy s Drug Recall spreadsheet. A copy of the drug recall notice for affected products will also be maintained in the recall section of the Nursing Station Inspection Electronic notification and postings will be made to alert Pharmacy personnel to look for specific recalled drugs during the monthly Nursing Station Review. J. The Pharmacy Purchasing Manager will insure that once confiscated, all recalled items will be sequestered, labeled as Recalled medications and properly stored in a secure area until they are picked up by or returned to the manufacturer. Recall products from a 340B site will be segregated and returned separately. K. The Pharmacy Purchasing Manager will process recalled drugs as directed by the manufacturer or regulatory agency and complete all necessary documentation to denote full compliance with the details of the recall. The completed Product Recall spreadsheet and all other documentations will be maintained. IV. CONTROLS: A. The Director of Pharmacy will regularly monitor drug recall notices to insure compliance with this policy. B. The Director of Pharmacy or designee will periodically review Pharmacy medication storage sites to insure compliance with recall notices as a part of the monthly Nursing Station Inspections. C. The Risk Manager will monitor the proper notification of patients who may have received recalled drugs with safety concerns of substantial clinical significance. Kenneth Gibbs President & CEO KG:FC:ld REFERENCES: INDEX DISTRIBUTION ORIGINATING DEPARTMENT :TJC Medication Management, American Society of Hospital Pharmacists :Recall, Drug :D (Pharmacy Staff, Selected Administrative Staff) :Pharmacy ATTACHMENT : Drug-Recall Report Form 7

Distributor FDA Recall notices received from various sources Manufacturer Review severity of recall notice and action(s) to be taken Have we purchased affected products in the past? YES NO Can vendor provide shipment info of affected products? NO Locate affected products (Satellite, Automatic Dispensing cabinet, etc) Check physical inventory at the location(s) Did pharmacy receive any affected products? YES NO Remove affected product from inventory Quarantine and contact Return Distributor to return affected product Record findings. Information will be shared during P&T meeting Fig. 1. Drug Recall Flowchart 8

ATTACHMENT B MAIMONIDES MEDICAL CENTER FOOD AND NUTRITION SERVICES POLICIES AND PROCEDURES Subject: Expired Products and Product Recall P & P # 3.B.13 (1) Page 1 of 1 Effective Date: Date Reviewed or Revised: Revised 9/17 9/17 Interdepartmental Approval: Marvo Forde POLICY: Food & Nutrition will discard any outdated food items, and remove food items that are recalled due to manufacturer s defect. PURPOSE: To establish a policy for handling products identified by the manufacturers for recall and for handling outdated items. PROCEDURE: 1. All food items that have reached the expiry date will be considered unsafe to use and will be removed from inventory. 2. All items will be checked carefully for the expiry dates to ensure that products are not used after the indicated expiry date. 3. Any unused food items left over after initial use will be discarded. 4. When there is an FDA alert, or a vendor alert, regarding a product being recalled, the lot number, and the manufacturer s name must be provided to the Department Director and Purchasing Manager. 5. If the alert matches the manufacturer s name and lot number, the products are pulled from the inventory/storage, and isolated in a secured location. The vendor will provide direction of whether the product will be discarded or return them for credit. 6. If the product does not meet the recall lot number, the vendor will send a verification report confirming that the product is not carried nor stocked for the product being recalled. CONTROL: The Food Service Management Team and Team Leaders are responsible for ensuring compliance to this policy/procedure by all staff members. 9